Enhanced chemiluminescence as a means of increasing the sensitivity of western blot assays for HIV antibody. NLM AIDSLINE Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Enhanced chemiluminescence as a means of increasing the sensitivity of western blot assays for HIV antibody.

J Virol Methods. 1994 Apr;47(1-2):153-64. Unique Identifier : AIDSLINE MED/94327722
Constantine NT; Bansal J; Zhang X; Hyams KC; Hayes C; University of Maryland School of Medicine, Department of; Pathology, Baltimore.


Abstract: Chemiluminescence indicator systems offer several advantages for diagnostic assays and have been used successfully to increase the sensitivity of antibody and antigen assays. A technique of enhanced chemiluminescence (ECL) was applied as a replacement for routine chromogenic substrates on HIV-1 Western blots. The results indicated that the enhanced chemiluminescence detection system increased the sensitivity by greater than 10-fold over routine chromogenic indicator systems when testing diluted, reactive sera. When testing 9 seroconversion panels, the use of ECL indicated that early detection of HIV infection was elicited in six panels up to 31 days (average 11.4 days) prior to detection by routine FDA-licensed Western blots, and could be detected in all panels up to 43 days (average 18.8 days) prior to detection by in-house Western blots. In no case was the ECL Western blot system less sensitive than any of the chromogenic Western blots, and in several cases the maximum potential of the ECL system for early detection of antibody could not be determined. The ECL system was capable of detecting antibodies to envelope antigens at a 20-fold increase over chromogenic Western blots. The time of detection of seropositivity by the ECL Western blot was equal to that of most ELISAs in 5 panels and was 31 days earlier than ELISA in one panel. Permanent documentation of Western blot profiles was accomplished using a simple instamatic camera system capable of detecting the chemiluminescence signal, and blots could be re-probed using a second sample.(ABSTRACT TRUNCATED AT 250 WORDS)
Keywords: Blotting, Western/*METHODS *Chemiluminescence Comparative Study Human HIV Antibodies/*BLOOD HIV Infections/BLOOD/*IMMUNOLOGY HIV Seropositivity/BLOOD/IMMUNOLOGY Sensitivity and Specificity Support, U.S. Gov't, Non-P.H.S. Time Factors JOURNAL ARTICLE

KWDblotting,western/KWDmethodsKWDchemiluminescencecomparativestudyhumanhivantibodies/KWDbloodhivinfections/blood/KWDimmunologyhivseropositivity/blood/immunologysensitivityandspecificitysupport,uKWDsKWDgov't,non-pKWDhKWDsKWDtimefactorsjournalarticle
941130
M94B0608


Copyright © 1994 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .